S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:GLMDGalmed Pharmaceuticals Stock Price, Forecast & News

$4.74
+0.21 (+4.64 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.44
Now: $4.74
$4.75
50-Day Range
$4.46
MA: $4.82
$5.69
52-Week Range
$3.02
Now: $4.74
$7.38
Volume97,689 shs
Average Volume89,490 shs
Market Capitalization$100.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Read More
Galmed Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.04 million
Book Value$3.30 per share

Profitability

Net Income$-20,460,000.00

Miscellaneous

Employees17
Market Cap$100.08 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$4.74
+0.21 (+4.64 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

How has Galmed Pharmaceuticals' stock price been impacted by COVID-19?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GLMD stock has increased by 12.6% and is now trading at $4.74.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Galmed Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Galmed Pharmaceuticals
.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Galmed Pharmaceuticals
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.05.
View Galmed Pharmaceuticals' earnings history
.

What price target have analysts set for GLMD?

9 equities research analysts have issued 1-year target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $8.00 to $33.00. On average, they expect Galmed Pharmaceuticals' stock price to reach $19.63 in the next year. This suggests a possible upside of 314.0% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
.

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Press coverage about GLMD stock has been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Galmed Pharmaceuticals
.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 465,500 shares, an increase of 23.8% from the June 15th total of 376,000 shares. Based on an average daily trading volume, of 80,800 shares, the short-interest ratio is currently 5.8 days. Currently, 3.2% of the company's stock are sold short.
View Galmed Pharmaceuticals' Short Interest
.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Exelixis (EXEL), Immunomedics (IMMU) and Ocular Therapeutix (OCUL).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 55, Pay $784.86k)
  • Mr. Yohai Stenzler, CFO & Controller (Age 37, Pay $155.34k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 35, Pay $165.43k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 53, Pay $242.52k)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 50, Pay $242.28k)

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (9.82%), BVF Inc. IL (8.52%), Ibex Investors LLC (4.67%) and Raymond James & Associates (2.53%).

Which major investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL.

Which major investors are buying Galmed Pharmaceuticals stock?

GLMD stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Raymond James & Associates, and Ibex Investors LLC.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $4.74.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $100.08 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.